Jul 2026· Pharmacology and Therapeutics· Vol 286, pp.
109088
· 0 citations· 234 references
Medicine
TL;DR
By achieving synergistic integration of delivery, activation, and potentiation, inorganic nanomaterials enhance both the efficacy and safety of STING-targeted immunotherapy, realizing the integrated functional advantage of "carrier-adjuvant-inducer" and offering a new paradigm for cancer immunotherapy.
Abstract
The cGAS-STING pathway serves as a central hub for DNA-triggered innate immune activation in tumors. Nevertheless, the clinical translation of stimulator of interferon genes (STING) agonists remains hindered by challenges such as rapid in vivo degradation, inefficient cytosolic delivery, and the risk of systemic inflammation. Inorganic nanomaterials, leveraging their high specific surface area, tunable size and morphology, and unique surface chemical properties, provide an ideal platform for the precise delivery and spatiotemporally controlled release of STING agonists. Furthermore, these materials can induce the release of double-stranded DNA (dsDNA) to activate STING while also synergistically potentiating STING activation through the induction of immunogenic cell death or the release of specific metal ions. This review highlights that the application of inorganic nanomaterials in STING pathway activation extends beyond simple agonist delivery to encompass precise spatiotemporal control and modulation of signal intensity. We systematically outline design strategies for inorganic platforms that facilitate agonist protection and stimuli-responsive release. Furthermore, we discuss their synergistic integration with therapeutic modalities, including radiosensitization, reactive oxygen species (ROS) induced DNA damage, and immunogenic cell death (e.g., pyroptosis and ferroptosis), ultimately contributing to the establishment of a cGAS-STING amplification immune circuit. By achieving synergistic integration of delivery, activation, and potentiation, inorganic nanomaterials enhance both the efficacy and safety of STING-targeted immunotherapy, realizing the integrated functional advantage of "carrier-adjuvant-inducer" and offering a new paradigm for cancer immunotherapy.
This review summarizes current advances in metal-ion-mediated cGAS-STING activation and examines how metal ions and metallic nanostructures integrate agonist delivery, intrinsic pathway activation, and tumor microenvironment modulation.
Yun-Qi Guo, Zhi-Hao Zhao, Liang-Can He et al.· ACS Nano Medicine· 0 citations
In vivo studies of both anti-PD-L1-responsive and resistant tumor models demonstrated that intratumoral delivery of bPEI-Thy/siPD-L1 NCs substantially reduced tumor growth and metastatic spread, induced apoptosis, alleviated immunosuppression, and extended survival.
Li-Qing Chen, Mong-Hsiu Song, Ming-Ji Jin et al.· Journal of Controlled Releas...· 0 citations
ABSTRACT STING agonists (e.g., cGAMP), which function as immunotherapeutic agents activating the stimulator of interferon genes (STING) pathway, hold promise for treating pediatric solid tumors including neuroblastoma. However, their clinical translation is hindered by limitations including burst release, short half‐li...
Yu-Bin He, Xiao Lu, Chang-Qing Yang et al.· Advancement of science· 0 citations
The stimulator of interferon (IFN) genes (STING) pathway has garnered considerable attention due to its significant potential in anti-cancer effect. However, cyclic dinucleotides (CDNs), which are natural agonists or their derivatives for STING, are often hindered by their inherent properties of poor transmembrane pe...
Li-Ru Shang, Lin Peng, Zhang-Ping Huang et al.· Molecular Pharmaceutics· 0 citations
In situ cancer vaccines exhibit promising therapeutic potential; however, their efficacy is constrained by limited antigen release, suboptimal spatiotemporal immune coordination, and adaptive immune resistance. In this study, we identify zinc ions (Zn2+) as synergistic agents with chemotherapeutics in modulating PANopt...